Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Targeting mTOR/GSK3 With Lithium Augmentation to Enhance and Sustain Rapid Antidepressant Actions of Ketamine in Adults With Treatment-Resistant Depression: A Precision Medicine Approach for Psychiatry


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT03290963

Organisation Name: Mayo Clinic

Overal Status: Withdrawn

Start Date: November 30, 2017

Last Update: August 16, 2018

Lead Sponsor: William V. Bobo, M.D.

Brief Summary: The purpose of this research study is to compare the antidepressant effect of lithium versus placebo in adults receiving ketamine. Lithium is available commercially for depression; ketamine is available commercially and can help the symptoms of depression; however, it has not been approved by the U.S. Food and Drug Administration (FDA) for this use. The FDA has allowed the use of this drug in this research study.

Conditions:
  • Treatment Resistant Depression


Total execution time in seconds: 0.26560401916504